In addition, new targeted therapies are in development to modulate hepcidin signaling, including the JAK1/JAK2 and type 1 kinase activin A receptor or activin receptor-like kinase-2 (ACVR1/ALK2) inhibitor momelotinib (discussed in greater detail in the “Treatment options for anemia resulting from JAK inhibition” section) [30, 31] and the ACVR1/ALK2 inhibitor INCB000928 [32]. This evidence concerns the gene JAK2 and anemia (phenotype).